Problem Definition
PharmaChain is a pharmaceutical distribution company with $4.2 billion in annual revenue and a 2.1% net margin. The company serves 8,000 independent and chain pharmacies and 340 hospitals across the U.S. Northeast, operating 6 distribution centers (DCs) and a fleet of 420 temperature-controlled trucks.
Over the past two years, PharmaChain has faced a margin squeeze from two directions. First, inventory carrying costs have risen 40% — from $85M to $119M annually — driven by specialty drug price inflation that has increased the average value of inventory on hand. Second, 6.2% of deliveries experience temperature excursions (periods where product is exposed to out-of-range temperatures), resulting in $38M in annual product waste from spoilage, disposal, and reorder costs.
The COO has retained your team to develop a plan that achieves two simultaneous objectives: cut $60M in annual operating costs and reduce the network-wide temperature excursion rate to under 2%. How would you approach this problem, and where would you look for the largest cost reduction opportunities?
Additional InformationAsk for more dataHide data
Provide if asked by the candidate:
- PharmaChain's top 3 competitors operate at 1.5-2.0% excursion rates; PharmaChain risks losing hospital contracts if compliance does not improve
- Specialty injectable drugs represent 38% of inventory value but 49% of carrying costs due to an 18% carrying cost rate (cold storage, insurance, obsolescence)
- Two DCs (DC2 and DC5) account for over 55% of all network excursion events despite handling 41% of total volume
- Automation technology (robotic pick-and-pack, automated cold chain monitoring) is available at $14M per DC installation cost
- PharmaChain has a 3-year window before two major hospital group contracts come up for renewal
- Average truck utilization is 68%; industry benchmark is 82%
- The company's current inventory management system is 12 years old and does not support demand-driven replenishment
Exhibit 3Temperature Excursion Root Causes (% of excursion events by DC)
| Root Cause | DC1 | DC2 | DC3 | DC4 | DC5 | DC6 | Network Avg |
|---|---|---|---|---|---|---|---|
| Loading dock exposure | 35 | 52 | 20 | 8 | 42 | 25 | 33 |
| In-transit equipment failure | 25 | 18 | 30 | 22 | 28 | 30 | 25 |
| Last-mile handoff delay | 20 | 15 | 25 | 38 | 18 | 22 | 22 |
| Warehouse zone transfer | 15 | 12 | 18 | 25 | 8 | 18 | 15 |
| Monitoring/documentation gap | 5 | 3 | 7 | 7 | 4 | 5 | 5 |
Insight Tiers:
- Level 1: Loading dock exposure is the single largest root cause network-wide (33%), and it dominates at DC2 (52%) and DC5 (42%) — precisely the kind of failure that warehouse automation eliminates through enclosed robotic loading systems.
- Level 2: DC4's remaining excursions (2.8% rate) are driven primarily by last-mile handoff delays (38%) and warehouse zone transfers (25%) — these are PROCESS failures, not infrastructure failures. This tells you that after automation solves the loading dock problem, the next improvement wave requires operational process redesign (handoff protocols, zone transition procedures), not additional capital spending. Candidates who propose "more automation" as a silver bullet miss this shift in root cause composition.
Source: PharmaChain case file
Question 1Structuring
Prompt: "How would you structure your analysis to identify where PharmaChain can achieve the $60M cost target while bringing excursions below 2%?"
Hint · Structuring
Build 3–4 branches that are specific to this client and question, not a generic framework. Check they don't overlap and together cover the problem.
Interviewer Guidance:
Provide the candidate with Exhibit 1 (DC Performance Comparison) after they lay out their initial structure. Let them refine their approach based on the data.
| Rating | Criteria |
|---|---|
| Good (3) | Identifies the two problems (carrying costs and waste) as separate workstreams. Mentions automation as a lever. Organizes by cost category (transportation, warehousing, inventory, waste). |
| Strong (4) | Recognizes the problems are LINKED — cold chain failures drive waste, which inflates effective inventory costs because spoiled product must be reordered. Structures by operational lever: (1) cold chain compliance via automation and monitoring, (2) inventory optimization via demand forecasting and safety stock reduction, (3) network efficiency via route optimization and DC utilization. Identifies DC2 and DC5 as priority targets from the exhibit. |
| Excellent (5) | All of the above, PLUS: Frames the problem as a TRADE-OFF challenge — DC2 shows that the cheapest DCs have the worst compliance, so pure cost reduction would worsen the excursion problem. Recognizes DC4 as the quality benchmark despite its high cost per case, and hypothesizes that DC4's high unit cost stems from fixed automation costs spread over low volume (1.8M cases). Proposes a phased approach: (1) quick wins via route optimization and truck utilization (68% vs. 82% benchmark), (2) medium-term automation rollout prioritized by excursion severity, (3) long-term inventory system modernization. Anchors the timeline to the 3-year hospital contract renewal window. |
Exhibit 1Distribution Center Performance Comparison
| DC | Annual Volume (M cases) | Cost per Case ($) | On-Time Delivery (%) | Temp Excursion Rate (%) | Avg Delivery Radius (mi) | Automation Level |
|---|---|---|---|---|---|---|
| DC1 | 2.8 | 3.90 | 96.5 | 5.8 | 120 | Low |
| DC2 | 3.4 | 3.20 | 93.5 | 9.4 | 160 | None |
| DC3 | 2.2 | 4.10 | 97.8 | 4.6 | 90 | Medium |
| DC4 | 1.8 | 4.80 | 99.1 | 2.8 | 85 | High |
| DC5 | 3.0 | 3.60 | 95.0 | 7.2 | 140 | Low |
| DC6 | 2.4 | 4.00 | 97.0 | 5.0 | 105 | Medium |
| Network | 15.6 | 3.84 wt avg | 96.1 wt avg | 6.2 wt avg | — | — |
Insight Tiers:
- Level 1: DC2 has the lowest cost ($3.20) but worst excursion rate (9.4%); DC4 has the highest cost ($4.80) but best compliance (2.8%). A strong correlation exists between automation level and excursion performance.
- Level 2: DC4's volume (1.8M) is the network's smallest — its high cost per case partly reflects fixed automation costs spread over fewer cases, not inherent inefficiency. At DC2-level volume (3.4M cases), DC4's automation model would yield a materially lower cost per case. Meanwhile, DC2's 160-mile delivery radius is the network's widest, compounding in-transit exposure time for temperature-sensitive products.
Possible Answer (Excellent):
A strong framework for this case would have three branches, each with 2-3 sub-items:
-
Cold Chain Compliance (addresses the excursion target)
- DC-level root cause analysis: which DCs drive the most excursions, and why?
- Technology gap assessment: what automation exists at high-performing DCs vs. low-performing ones?
- Investment case: what is the ROI of upgrading the worst performers?
-
Inventory Cost Optimization (addresses the carrying cost inflation)
- Product mix analysis: which drug categories drive disproportionate carrying costs?
- Demand forecasting: can days-on-hand be reduced without stockout risk?
- System modernization: does the 12-year-old inventory system constrain optimization?
-
Network and Transportation Efficiency (addresses remaining cost gap)
- Fleet utilization: why is truck utilization 14pp below industry benchmark?
- Route optimization: can delivery radii be reduced through DC coverage rebalancing?
- Volume reallocation: should case volume shift between DCs based on true total cost?
"So What?" Cascade:
- Level 1: PharmaChain has a cost problem and a quality problem
- Level 2: The cost problem and quality problem are inversely correlated at the DC level — cheapest DCs have worst quality — meaning cost-cutting without quality awareness will accelerate contract losses
- Level 3: The solution requires INVESTING in the worst-performing DCs (higher short-term cost) to unlock waste savings and protect revenue — spending money to save more money
Source: PharmaChain case file
Question 2Numeracy
Prompt: "PharmaChain is considering automating DC2 and DC5 to match DC4's cold chain technology. Using the following assumptions, calculate the annual net savings and payback period."
Hint · Numeracy
Write the formula before you plug in numbers, keep units and zeros explicit, and sanity-check the order of magnitude at the end.
Assumptions (provide to candidate):
| Parameter | Value |
|---|---|
| Automation capital cost | $14M per DC |
| Useful life (straight-line depreciation) | 5 years |
| Post-automation excursion rate | 2.5% at both DCs |
| Increase in operating cost per case (maintenance, energy) | $0.60 |
| Waste cost per temperature excursion event | $40 (disposal + reorder) |
| No change in case volume at either DC | — |
Try it first, then checkShow model answerHide model answer
Step-by-Step Solution
Step 1 — Calculate waste reduction
| DC2 | DC5 | |
|---|---|---|
| Annual cases (M) | 3.4 | 3.0 |
| Current excursion rate | 9.4% | 7.2% |
| Post-automation excursion rate | 2.5% | 2.5% |
| Excursion reduction (pp) | 6.9 | 4.7 |
| Excursion cases eliminated | 234,600 | 141,000 |
| Waste savings at $40/case ($M) | 9.4 | 5.6 |
| Total waste savings | $15.0M |
Step 2 — Calculate additional operating costs
| Calculation | Result | |
|---|---|---|
| Combined volume | 3.4M + 3.0M | 6.4M cases |
| Cost increase per case | — | $0.60 |
| Additional annual operating cost | 6.4M x $0.60 | $3.8M |
Step 3 — Calculate depreciation
| Calculation | Result | |
|---|---|---|
| Total capital investment | 2 DCs x $14M | $28M |
| Annual depreciation | $28M / 5 years | $5.6M |
Step 4 — Calculate net annual savings
| Metric | Calculation | Result |
|---|---|---|
| Waste savings | — | $15.0M |
| Less: additional operating cost | — | ($3.8M) |
| Net cash savings | $15.0M - $3.8M | $11.2M |
| Less: depreciation | — | ($5.6M) |
| Net P&L impact | $11.2M - $5.6M | $5.6M |
Step 5 — Payback period
| Calculation | Result | |
|---|---|---|
| Total investment | — | $28M |
| Annual cash savings | — | $11.2M |
| Payback period | $28M / $11.2M | 2.5 years |
Key Insight: The $11.2M from DC2/DC5 automation covers roughly 19% of the $60M target. Candidates should note that additional savings must come from other levers — inventory optimization on specialty injectables ($58.5M in carrying costs at 32 days on hand) and transportation efficiency (68% vs. 82% utilization gap) are the largest remaining pools.
Reality Check: A 2.5-year payback on supply chain automation is within normal industry ranges (2-4 years). The $5.6M P&L impact represents a 6.3% improvement on PharmaChain's $88.2M net income ($4.2B x 2.1%).
Question 3Judgement & Insights
Prompt: "Looking at Exhibits 1 and 2, the COO asks: 'DC2 is our lowest-cost center. Should we replicate its operating model across the network to close the cost gap?' What is your response?"
Hint · Judgement & Insights
Read the exhibit title, axes and units first. Lead with the ‘so what’, then back it with one or two numbers.
Interviewer Guidance:
This question tests whether the candidate spots the trap in the data. Push back gently if the candidate agrees with the COO's framing.
| Rating | Criteria |
|---|---|
| Good (3) | Disagrees with replicating DC2. Points out that DC2 has the highest excursion rate (9.4%) and its low cost per case ($3.20) likely comes from underinvestment in cold chain infrastructure. Notes that higher excursion rates drive waste costs not visible in the cost-per-case metric. |
| Strong (4) | Quantifies the hidden cost. DC2's 9.4% excursion rate on 3.4M cases = 319,600 excursion events x $40 = $12.8M in waste. Its "true" cost per case is $3.20 + ($12.8M / 3.4M) = $3.20 + $3.76 = $6.96/case — the HIGHEST in the network when waste is included. Contrasts with DC4: $4.80 + (50,400 x $40 / 1.8M) = $4.80 + $1.12 = $5.92/case. DC4 is actually cheaper on a total-cost basis. |
| Excellent (5) | All of the above, PLUS: References Exhibit 2 to connect inventory insights — Specialty Injectable carrying costs ($58.5M) suggest the excursion problem disproportionately impacts the highest-value products. Notes that DC4's higher cost per case is partly a SCALE problem: at 1.8M cases, DC4 has the lowest volume, meaning fixed automation costs are spread thinnest. If DC4's automation model were deployed at DC2 (3.4M cases), fixed costs per case would drop by roughly 47%. Recommends replicating DC4's MODEL at DC2's SCALE. Connects to the hospital contract risk: losing contracts due to excursions would reduce revenue, further squeezing the 2.1% margin. |
Exhibit 2Inventory Carrying Costs by Drug Category (2025)
| Drug Category | Share of Inventory Value (%) | Avg Days on Hand | Carrying Cost Rate (%) | Annual Carrying Cost ($M) |
|---|---|---|---|---|
| Generic Oral | 12 | 18 | 8 | 8.2 |
| Brand Oral | 23 | 22 | 12 | 23.5 |
| Specialty Injectable | 38 | 32 | 18 | 58.5 |
| Biosimilars | 12 | 28 | 15 | 15.5 |
| Controlled Substances | 15 | 12 | 10 | 13.3 |
| Total | 100 | — | — | 119.0 |
Insight Tiers:
- Level 1: Specialty Injectable drugs are 38% of inventory value but 49% of carrying costs ($58.5M of $119M) due to their 18% carrying cost rate and 32 days on hand — this is the dominant cost driver.
- Level 2: Biosimilars carry 28 days on hand despite being lower-cost substitutes for specialty drugs. This elevated buffer likely reflects formulary uncertainty or slow physician adoption, not genuine demand variability. Reducing Biosimilar days from 28 to 18 (matching Generic Oral) could save approximately $5.5M — a quick win that also validates the demand forecasting model before tackling the larger Specialty Injectable inventory pool.
True Cost Per Case Summary (for interviewer reference):
| DC | Operating Cost/Case ($) | Waste Cost/Case ($) | True Total Cost/Case ($) |
|---|---|---|---|
| DC1 | 3.90 | 2.32 | 6.22 |
| DC2 | 3.20 | 3.76 | 6.96 (highest) |
| DC3 | 4.10 | 1.84 | 5.94 |
| DC4 | 4.80 | 1.12 | 5.92 (lowest) |
| DC5 | 3.60 | 2.88 | 6.48 |
| DC6 | 4.00 | 2.00 | 6.00 |
Waste cost per case = excursion rate x $40 waste per excursion event
"So What?" Cascade:
- Level 1: DC2 is not actually the lowest-cost center when waste is included
- Level 2: The data reveals an inverse relationship between apparent efficiency and true total cost — optimizing for visible cost per case while ignoring waste creates a false economy
- Level 3: The right strategy is to combine DC4's quality model with DC2's scale advantage, requiring capital investment now to prevent revenue loss at hospital contract renewal
Source: PharmaChain case file
Question 4Synthesis
Prompt: "You have five minutes with the COO. What is your recommendation?"
Hint · Synthesis
Answer first: the recommendation, two or three reasons with numbers, then risks and next steps.
Interviewer Guidance:
| Rating | Criteria |
|---|---|
| Good (3) | Recommends automation at DC2 and DC5 with clear financial justification ($11.2M net cash savings, 2.5-year payback). Mentions inventory optimization and route efficiency as additional levers. States the $60M target is achievable. |
| Strong (4) | Structures the recommendation in three phases with specific numbers: (1) Automate DC2 and DC5 — $11.2M annual cash savings, addresses worst excursion sites, 2.5-year payback; (2) Optimize specialty injectable inventory — reduce days on hand from 32 toward 20-22, targeting $15-18M in carrying cost reduction; (3) Improve truck utilization from 68% to 78-80% through route optimization — targeting $12-15M in transportation savings. Total identified: $38-44M, with the remaining gap from extending automation to DC1 and DC6 and modernizing the 12-year-old inventory system. Acknowledges the $60M target requires aggressive execution on all fronts. |
| Excellent (5) | All of the above, PLUS: Frames the recommendation as a REVENUE PROTECTION play, not just cost cutting — the 3-year hospital contract window means the cost of inaction ($38M/year in waste plus potential contract losses on a $4.2B revenue base) exceeds the cost of investment ($28M one-time). Addresses risk: phase automation starting with DC2 (largest volume, worst excursion rate) for maximum impact and proof of concept before DC5. Proposes success metrics: (1) network excursion rate below 2% within 18 months, (2) $30M in annualized savings by end of year 2, (3) hospital contract retention at renewal. Ends with a clear ask: "Approve $28M in automation capital for DC2 and DC5, and fund a 6-month inventory system upgrade study." |
Possible Recommendation Structure (Excellent):
"We recommend a three-phase plan that delivers $60M in annual savings while cutting excursions below 2%, timed to the hospital contract renewal cycle."
Phase 1 (Months 1-12): Automate DC2 and DC5 — $28M investment, $11.2M annual cash savings, 2.5-year payback. This eliminates 55% of network excursion events by targeting loading dock exposure, the dominant root cause at both sites. Start with DC2 (highest volume, worst excursion) as proof of concept.
Phase 2 (Months 6-18): Optimize inventory and routes — Reduce Specialty Injectable days on hand from 32 to 22 and Biosimilar days from 28 to 18, targeting $18-20M in carrying cost savings. Simultaneously increase truck utilization from 68% toward 80% through route consolidation, targeting $12-15M in transportation savings.
Phase 3 (Months 12-30): Modernize and scale — Replace the 12-year-old inventory system to enable demand-driven replenishment. Extend automation to DC1 and DC6 based on Phase 1 learnings. Target remaining $15-18M gap.
"The total cost of inaction exceeds $38M annually in waste alone, before accounting for contract risk. We need $28M approved this quarter to begin."
"So What?" Cascade:
- Level 1: Automate the two worst DCs, optimize inventory, improve fleet utilization
- Level 2: The sequence matters — automation first because it addresses both objectives (cost and compliance) simultaneously, and it de-risks the hospital contract renewals
- Level 3: This is fundamentally a revenue protection investment disguised as a cost reduction program; the real risk is not the $28M capital outlay but the $4.2B revenue base exposed by a 6.2% excursion rate
Contributed by CaseDrill practice community